Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.69 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.63 |
| ▸ | POLA1 | P09884 | 1/20 | 0.63 |
| ▸ | POLG | P54098 | 1/20 | 0.63 |
| ▸ | FAP | Q12884 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | NSD3 | Q9BZ95 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.49 |
| ▸ | NSD2 | O96028 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28797052 | 0.87 | FGFR1 (0.74) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL3302566 | 0.85 | FGFR1 (0.71) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL13114340 | 0.84 | FGFR1 (0.77) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL8397101 | 0.83 | FGFR1 (0.68) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL30030144 | 0.83 | FGFR1 (0.68) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL12393103 | 0.82 | FGFR1 (0.82) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL49373 | 0.82 | FGFR1 (1.00) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL29365535 | 0.82 | FGFR1 (1.00) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL17319263 | 0.82 | FAP (0.74) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL13983477 | 0.82 | CYP3A4 (0.76) | FAPCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238753-A1 | PROCESS FOR THE PREPARATION OF ADEFOVIR DIPIVOXIL | MYLAN LABORATORIES LIMITED (IN) | 2012-09-20 | — | — | US | disclosed |
| US-20120238753-A1 | PROCESS FOR THE PREPARATION OF ADEFOVIR DIPIVOXIL | MYLAN LABORATORIES LIMITED (IN) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238753-A1 | PROCESS FOR THE PREPARATION OF ADEFOVIR DIPIVOXIL | DCTD, PEPD, MTAP | FGFR1 4222/4885SLC22A6 2825/4885ABCB11 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.